1.Analysis of Effectiveness of THP-based Regimens in Treating 90 Cases of Hematopoietic Malignancies
Journal of Medical Research 2006;0(10):-
Objective To observe the effect of Pirarubicin (THP) with other chemical agents in treating hematopoietic Malignancies. Methods 90 inpatients diagnosed as hematopoietic malignancies between January 2000 to December 2005 were treated with THP with other chemical agents. 30 had not been treated previously ,(untreated) while 60 were relapsing or resistant to previous treatment. Acute leukemia(AL) was 60 cases, Malignancy lymphoma(ML) was 21 cases, Multiple myeloma(MM) was 9 cases. Results The complete response(CR) rate among AL untreated and relapsing/resistant groups were 91.7% and 38.5%; 71.5% of response rate were malignancy Lymphoma(ML); 67.8% of response rate ware multiple myeloma(MM).The total response rate was 80.0%. The main side-effect of THP is bone marrow depression which led to fever and bleeding with rates 30.2%, 20.5%. The non-bone marrow side effects were tolerable. Damage to the liver was a prominent occurrence 20.8%. Conclusions THP was effective as the first line anti-tumor drug with other chemical agents in treating hematopoietic malignancies, its side-effects were mild and well tolerable.
2.Study of Sodium Arsenite in Treating 30 Cases of Adult Chronic Myeloid Leukemia
Journal of Medical Research 2006;0(12):-
Objective To estimate the effect of sodium arsenite(AS2O3)in treating adult chronic myeloid leukemia(CML).Methods 30 inpatients diagnosed as CML from December 2002 to January 2008 were treated with AS2O3,of which 16 cases had not been treated previously,while 14 cases were relapsing or resistant to previous treatment.Results The complete response rate was 63.3%,while the partial response rate was 20.0%,non-response rate was 16.7%.The total response rate was 83.3%.Conclusion AS2O3 is an effective drug in treating CML with side effects being mild and well tolerance.
3.Expression of myostatin gene mRNA in the muscle tissue from 75 patients with muscular weakness
Chinese Journal of Neurology 2014;47(11):772-775
Objective To investigate myostatin gene mRNA expression in the muscle tissue from patients with muscle weakness suffering from different illness.Methods The clinical data of our patients were all from the Muscular Disease Center,Department of Neurology,People' s Liberation Army General Hospital.A total of 75 patients suffered from muscular weakness were included consecutively.Skeletal muscle biopsies were obtained with informed consent from all 75 patients.The diagnosis was confirmed by two senior doctors for muscular disease according to the clinical feature,the results of electromyography,serum creatine kinase activity and histopathological examination.Among of them,21 cases were diagnosed as polymyositis,15 cases progressive muscular dystrophy,5 cases neurogenic amyotrophy,4 cases chronic muscle fiber damage,4 cases mitochondrial myopathy,4 cases lipid storage myopathy,4 cases myotonic dystrophy,3 cases muscular dystrophy in adults,2 cases dermatomyositis,and 2 cases inclusion body myositis.There were 2 cases characterized by pure high activity of creatine kinase.And the other 9 cases were diagnosed as non-neuromuscular disease.The expression of myostatin gene mRNA in muscle tissue was evaluated by reverse transcription polymerase chain reaction method,with glyceraldehyde-3-phosphate dehydrogenase as internal reference.Results The expression of myostatin gene mRNA was detected in 63 patients,but not in other 12 cases,and the percentage of positive expression was 84%.The expression index was with great variation,from 0 to 3.52.In positive cohort,the index was correlated positively with the duration of disease (r =0.236,P =0.041).The activities of creatine kinase in positive expression cohort were higher than that of negative one,but nonsignificantly.Conclusion The expression of myostatin gene mRNA in muscle tissue may not correlate to the entity of atrophic muscular disease because of its great variation.
4.Neuroprotective effect of acteoside against MPTP-induced mouse model of Parkinsons disease
Chinese Pharmacological Bulletin 1987;0(01):-
Aim To study the neuroprotective effect of Acteoside against MPTP-induced mouse model of Parkinsons disease (PD) and its mechanism. Methods The behavioral testing of C57 mice was assessed using spontaneous movement and rotarod test. DA levels in striatum were measured using HPLC-EC. Dopaminergic neurons in the substantia nigra were observed by immunohistochemical staining with an anti-Tyroxine hydroxylase (TH) antibody. Moreover, the mechanism of the neuroprotective effect of acteoside was investigated using Western blot analysis with an anti-?-synuclein antibody in the substantia nigra and striatum. Results ① Compared with control, MPTP lesion significantly reduced the number of spontaneous movement and latent period of mice on the rotating rod (both P
5.The application of proteomics technology in drug study
Chinese Pharmacological Bulletin 2003;0(08):-
Recently,the techniques for proteomics have made remarkable progress.They are widely used in various fields of life sciences,providing strong technical supports for relevant researches.Especially,proteomics technology has made prominent contributions to drug development and mechanism studies,magnificently improving the efficiency of discovering new drugs.This paper summarizes the classical method and new technology of proteomics.Also,its applications in drug study,including targets screening,mechanism studies,drug toxicology,researches of resistance mechanisms and clinical medical studies have been reviewed.
6.Expression of Induced Nitric Oxide Synthase and Its Significance of Rats′ Kidney after Ischemia-Reperfusion
Journal of Applied Clinical Pediatrics 2006;0(17):-
Objective To investigate the expression levels and the roles of induced nitric oxide synthase(iNOS) in rats′ kidney after interruption of blood flow and the following ischemia-reperfusion(IR)injury.Methods Rats were divided into 3 groups:interruptions(5,15,30 min),IR(2,5,8,24,48,72 h),control groups.They were killed at different time points.Kidney tissue samples were studied by immunohistochemical method.Results iNOS increased significantly(P
7.Prevention and treatment of infections in cardiac transplant recipients
Tongbing ZHAO ; Pu WANG ; Zhenzhong GUAN
Chinese Journal of Organ Transplantation 1997;18(4):214-215
The regularity and the preventive and curative measures about the post-operative infections in 3 orthotopic cardiac transplant recipients were reviewed.The results showed that the bacterial infections and the opportunistic fungal infections were common within 1~2 months after the cardiac transplantation.The sensitive antibiotics could completely control the infections.More than 3 months after surgery,the infections were gradually reduced.It was suggested that the prevention and treatment of the post-operative infections should be reinforced in the early stage of transplantation.
9.Application of the PD-1 antibody in melanoma therapy
Yanhong ZHAO ; Pu SONG ; Tianwen GAO
Chinese Journal of Clinical Oncology 2016;43(13):589-592
A melanoma is a highly malignant tumor that originates from melanocytes in the skin, mucosa, or tunica pigmentosa. The incidence and mortality rate of cutaneous melanoma are increasing annually. However, the efficacy of traditional therapy is extremely limited because of its low sensitivity and high toxicity. The application of the anti-CTLA-4 antibody and the BRAF inhibitor dramatically improves the overall survival of patients with advanced melanoma. However, their limited benefit ratio and high drug resistance curtail the use of anti-CTLA-4. Since the US Food and Drug Administration approved the use of the anti-PD-1 and anti-PD-L1 antibodies for ad-vanced melanoma in 2014, a significant survival benefit has been observed in patients with advanced melanoma. This review aims to highlight the applications of the anti-PD-1 antibody (pembrolizumab, nivolumab, and pidilizumab) and the anti-PD-L1 antibody (MP-DL3280A, BMS-936559, and MEDI4736) in the clinical treatment of melanoma by succinctly summarizing the results of recent reports.
10.Expressions of Kaposi′ s sarcoma-associated herpesvirus type 8-associated microRNAs k12-1 and k12-12 in Kaposi′s sarcoma and their significance
Xiujuan WU ; Zongfeng ZHAO ; Xiongming PU
Chinese Journal of Dermatology 2015;(12):860-863
Objective To measure the expressions of Kaposi′s sarcoma-associated herpesvirus type 8 associated-microRNAs k12-1 (kshv-miR-k12-1)and k12-12 (kshv-miR-k12-12)in Kaposi′s sarcoma tissue, and to assess their relationship with pathological stage and lesion area of Kaposi′s sarcoma, HIV infection, and human herpesvirus type 8 (HPV-8)infection. Methods Totally, 18 paired tissue specimens stored in liquid nitrogen from Kaposi′ s sarcoma lesions and paralesional skin were collected. Total RNAs were extracted from these specimens by using Trizol reagent, and reversely transcribed into cDNA. SYBR Green real-time fluorescence-based quantitative PCR was performed to measure the expressions of kshv-miR-k12-1 and kshv-miR-k12-12 in these specimens. The relationship of kshv-miR-k12-1 and kshv-miR-k12-12 expressions with the pathological stage and lesion area of Kaposi′s sarcoma, HIV and HPV-8 infections was analyzed. Results Compared with paralesional normal skin, Kaposi′s sarcoma lesions showed significantly increased expressions of kshv-miR-k12-1 (2-ΔΔCt: 1.016 ± 1.645 vs. 0.029 ± 0.019, t = 2.542, P = 0.016)and kshv-miR-k12-12 (2-ΔΔCt: 2.104 ± 1.973 vs. 0.102 ± 0.093, t = 4.301, P = 0.000). There were no significant differences in the expressions of kshv-miR-k12-1 or kshv-miR-k12-12 between patients with HIV or HPV-8 infection and those without, among patients with different pathological stages of Kaposi′s sarcoma, or among patients with different lesion areas (all P > 0.05). Conclusion Both kshv-miR-k12-1 and kshv-miR-k12-12 are highly expressed in Kaposi′s sarcoma, but neither of their expressions is related to HIV or HPV-8 infection, pathological stage or lesion area of Kaposi′s sarcoma.